NCT03212651View on ClinicalTrials.gov

Study Evaluating Neoadjuvant Pembrolizumab Monotherapy in Patients With Muscle-Invasive Bladder Cancer to Explore in Vivo the Mechanisms of Action of Pembrolizumab

PHASE2CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

October 17, 2017

Primary Completion Date

July 18, 2019

Study Completion Date

December 13, 2019

Conditions
Bladder Cancer
Interventions
DRUG

Pembrolizumab

Pembrolizumab 200mg IV infusion

Trial Locations (1)

94805

Gustave Roussy, Villejuif

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Gustave Roussy, Cancer Campus, Grand Paris

OTHER

NCT03212651 - Study Evaluating Neoadjuvant Pembrolizumab Monotherapy in Patients With Muscle-Invasive Bladder Cancer to Explore in Vivo the Mechanisms of Action of Pembrolizumab | Biotech Hunter | Biotech Hunter